

HPV Vaccination Update

On October 7, 2016, the FDA approved the use of a 2-dose schedule for 9vHPV vaccine in younger adolescents *beginning vaccination at 9 through 14 years.*

The package insert is available

at <http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf>

The CDC encourages clinicians to begin now to implement the 2-dose schedule in their practices to protect their teen patients from HPV cancers.

- The first HPV vaccine dose is routinely recommended at 11-12 years old. The second dose of the vaccine should be administered 6 to 12 months after the first dose.
 - This recommendation will make it easier for providers and parents to protect younger adolescents by reducing the number of doses and visits.
- Adolescents aged 9 through 14 years who have already received two doses of HPV vaccine less than 6 months apart, will require a third dose.
- Teens and young adults who start the series at ages 15 through 26 years will continue to need three doses of HPV vaccine to protect against cancer-causing HPV infections.
- Three doses are recommended for people with weakened immune systems aged 9-26 years.

The PPOC, through the learning community webinar series "Enhancing HPV Vaccination Rates to Prevent Adult Cancers" is collaborating with practices to reach a target goal of HPV vaccine completion rates of 80% for both male and female 9-13 year olds by the end of 2017. We will keep you updated with more details as they become available.